Feb 22, 2021
Exact Sciences to participate in March investor conferences
Feb 16, 2021
Exact Sciences to Acquire Ashion Analytics and Enter Research Collaboration with City of Hope's Genomics Institute, TGen
Feb 16, 2021
Exact Sciences Announces Fourth Quarter 2020 Results
Feb 01, 2021
Exact Sciences schedules fourth quarter 2020 earnings call
Jan 13, 2021
Exact Sciences Licenses Targeted Digital Sequencing Method to Extend Leadership in Precision Oncology
Jan 12, 2021
New Prospective Data Demonstrate Low False-Positive Rate for Screening Average-Risk People Age 45-49 for Colorectal Cancer with Cologuard®
Jan 05, 2021
Exact Sciences Completes Acquisition of Thrive Earlier Detection, Creating a Leader in Blood-Based, Multi-Cancer Screening
Dec 09, 2020
RxPONDER Study Results Demonstrate that the Oncotype DX® Test Can Now Spare Chemotherapy Use in the Majority of Women with Node-positive Early-stage Breast Cancer
Nov 23, 2020
Exact Sciences to participate in December investor conference
Oct 27, 2020
Exact Sciences Commends Task Force for Draft Updated Guidelines that include Colorectal Cancer Screening Beginning at Age 45
Oct 09, 2020
Exact Sciences schedules third quarter 2020 earnings call
Aug 03, 2020
Exact Sciences to participate in August investor conference
Jul 30, 2020
Exact Sciences Announces Second Quarter 2020 Results
Jul 08, 2020
Exact Sciences schedules annual meeting, second quarter 2020 earnings call
Jun 16, 2020
Oncotype DX Genomic Prostate Score® Result Shows for the First Time the Value of the Test to Guide Treatment Plans for Unfavorable Intermediate-Risk Prostate Cancer Patients
May 29, 2020
Exact Sciences Showcases Continued Progress in Cancer Diagnostics at ASCO 2020
May 26, 2020
Exact Sciences to participate in June investor conferences
May 14, 2020
New Oncotype DX® Real-world Evidence Shows for the First Time the Practice-changing Impact of TAILORx Results
May 06, 2020
Exact Sciences Announces First Quarter 2020 Results
May 05, 2020
New Model Shared at Digestive Disease Week (DDW) Demonstrates the Value of Cologuard® When Using Real-World Adherence Rates for Comparing Colorectal Cancer Screening Methods